ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Ginkgo gets $70 million to scale COVID-19 testing

by Melody M. Bomgardner
June 5, 2020 | APPEARED IN VOLUME 98, ISSUE 22

 

Boston-based Ginkgo Bioworks has raised $70 million from Illumina and other backers to build infrastructure for large-scale COVID-19 testing. Public health experts say millions of tests per day are needed to control the epidemic in the US; large-scale testing is also critical to reopening schools and businesses. Ginkgo will use the funds to deploy automation tools in combination with Illumina’s next-generation sequencing technology to read and process tens of thousands of RNA samples in parallel.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment